Emergent BioSolutions Announces Initiation of Phase Ib/II Study of TRU-016 in Combination with Bendamustine for Chronic Lymphocytic Leukemia

ROCKVILLE, Md., Jan 25, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced the initiation of a Phase Ib/II study (16201) of TRU-016 for chronic lymphocytic leukemia (CLL). TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical (SMIP(TM)) protein therapeutic in development for the treatment of B-cell malignancies. TRU-016 is [...]

February 1, 2011  Tags: , , , , , ,   Posted in: Clinical trial, Emergent BioSolutions, Leukemia, Research and development, fuad el-hibri  No Comments

CEO took roundabout path to Emergent

By Marjorie Censer
Monday, January 3, 2011
Fuad El-Hibri has lived in all sorts of exotic locales, working for Citicorp in Saudi Arabia, consulting for Booz Allen Hamilton in Indonesia and establishing mobile telecommunications businesses in Russia, Venezuela and El Salvador.
But getting started in his current position as chief executive of Rockville-based pharmaceutical company Emergent BioSolutions took [...]

January 7, 2011  Tags: , , , , ,   Posted in: Biosolutions, Business, CEO, Department of Health and Human Services, El-Hibri, Emergent BioSolutions, Research and development, Trubion Pharmaceuticals, Yale University, fuad, fuad el-hibri  No Comments

Emergent BioSolutions to Participate in June 2010 Investor Conferences

Fuad El-Hibri, CEO of Emergent BioSolutions Inc., announces that the company will be participating in the following investor conferences during June 2010:

The Jefferies & Company 2010 Global Life Sciences Conference
New [...]

June 7, 2010  Tags: , , , , , ,   Posted in: Business, Emergent BioSolutions, Health Care, Healthcare Conference, fuad el-hibri  No Comments